A Omni, the only digital platform for medication plans that works at any pharmacy in Brazil, welcomes the investment fund Norte Ventures and announces its third round in less than two years of operation in the health market. The investor joins to contribute to the strategy for future rounds of capital, with greatknow howin this segment.
The startup does not disclose its market value, but confirm that it was avaluationsimilar to what was practiced at the time of Greenrock's entry, that contributed 10 million reais, in May of this year.
Omni Saúde was founded in May 2023 by an entrepreneur in the health sector, Fernando Domingues, co-founder of Conexa Saúde, largest independent Telemedicine platform in Latin America and Digital Health Ecosystem, and from Cannect Life, medical cannabis marketplace that has already raised over 30 million reais, and by Leopoldo Veras, professional with over 25 years of experience in health management and experience with health plan operators, healthtechs, benefit administrators and prescription drug plan operators
Considered the first company to offer a medication plan that works at any pharmacy in Brazil, with an average cost of R$ 25 per employee, Omni aims to make the benefit indispensable for the HR sector of companies from different industries, providing a fundamental role in the democratization of access to medications. With a focus on user experience, the company has already sold more than 15 thousand medication plans, representing a triple growth just in the first quarter of 2024, compared to last year. Omni aims to double the number of lives in the second half of the year, reaching 50 thousand, which would result in an annual revenue of around R$10 million.Developed to serve employees of medium and large companies, a healthtechalready has several renowned clients such as, Dasa, Spoleto, Alper Insurance, Qualicorp, Riachuelo, Vitta/Stone, among others
"This investment will allow us to strengthen our internal operations", optimize processes and invest even more in the health of our clients' employees. The ability to expand our team and implement advanced technologies is essential to maintain our leadership position and meet the growing demands of the market, comment Fernando Domingues, co-founder and CEO of Omni. "Knowing about Norte Ventures' interest in co-investing in companies with high growth potential", this funding aims to enhance our commitment to providing significant advancements to tackle the challenges in the pharmaceutical sector and revolutionize pharmaceutical care. The partnership with Norte is a testament to the trust in our vision and the transformative impact that our technologies can have on people's health and well-being, complement
"We have known Fernando since Cannect and Conexa and he has assembled a very impressive team at Omni". The company addresses a relevant pain point, taking into account the high number of chronic patients in Brazil and the lack of coverage from health plans for this type of expense. With a superior value proposition and product and significant traction, the decision to invest was relatively 'easy'. Finally, we are happy to co-invest again with Greenrock, that brings a very strong validation in the healthcare sector, says Pedro Teo, partner at Norte Ventures
To fill this gap in pharmaceutical assistance in the Brazilian supplementary health system, a healthtechworks also through the promotion of information and the raising of awareness of the patient and the entire ecosystem about the rational and safe use of medications, as well as reinforcing the importance of adherence to treatment, mainly in cases of chronic diseases, in addition to the dangers of self-medication.
The company still has angel investors, like Jaime de Paula, founder of Neoway, Massanori Shibata Jr, CEO of Dr. Consultation, co-founder and controller of the Spoleto brands, Paulo Yoo, ecosystem and innovation director of Dr. Consultation, and Jorge Oliveira, executive director of Unimed Nacional
In June 2023, Omni received investmentseedof R$5 million, led by VEC Investments.
